10. シャルコー・マリー・トゥース病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
(RS)-baclofen
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
(RS)-baclofen, naltrexone hydrochloride and D-sorbitol
Pharnext SA
2021 Phase 3 NCT04762758 Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
ACE-083
Acceleron Pharma, Inc.
2019 Phase 2 NCT03943290 Canada;Spain;United States;
2017 Phase 2 NCT03124459 United States;
ACIDO ASCORBICO
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
ACIDO ASCORBICO DC.IT
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
Ascorbic acid
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2006 Phase 2 NCT00271635 Netherlands;
Chiba University
2019 Phase 1 JPRN-UMIN000036332 Japan;
New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.
2005 Phase 1,2 JPRN-UMIN000001535 Japan;
SHIOHAMA TADASHI
2019 Phase 2 JPRN-jRCTs031190109 Japan;
Ascorbic acid (Vitamin C)
Wayne State University
2007 Phase 2/Phase 3 NCT00484510 United States;
Ascorbic acid vit C
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
BACLOFENE
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Baclofen
Pharnext
2010 - EUCTR2010-023097-40-FR France;
CEBION 500*20CPR MAST
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
CEBION 500MG 20CPR MAST.ARAN
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
Coenzyme Q10
Memorial Medical Center
2007 Phase 1/Phase 2 NCT00541164 United States;
D-BIOTIN
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France;
D-SORBITOL
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
ElleOne
HÔPITAUX UNIVERSITAIRES DE STRASBOURG
2015 Phase 2 EUCTR2015-001716-36-FR France;
FLX-787-ODT (orally disintegrating tablet)
Flex Pharma, Inc.
2017 Phase 2 NCT03254199 United States;
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France;
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France;
Mexiletine
University of Rochester
2015 Phase 2 NCT02561702 United States;
NALTREXONE CLORIDRATO
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
NALTREXONE HYDROCHLORIDE
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Naltrexone
Pharnext
2010 - EUCTR2010-023097-40-FR France;
Naltrexone hydrochloride
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Non applicable
Pharnext
2010 - EUCTR2010-023097-40-FR France;
PXT3003
Pharnext
2010 - EUCTR2010-023097-40-FR France;
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2017 Phase 3 NCT03023540 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
PXT3003 Dose 1
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 Dose 2
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 Dose 2 (equivalent to twice Dose 1)
Pharnext
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 High Dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 Intermediate Dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 Low dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 dose 1
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2015 Phase 3 NCT02579759 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 dose 2
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2015 Phase 3 NCT02579759 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
RS-BACLOFEN
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
SODIO ASCORBATO DC.IT
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
SORBITOLO
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Sorbitol
Pharnext
2010 - EUCTR2010-023097-40-FR France;
ULIPRISTAL ACETATE
HÔPITAUX UNIVERSITAIRES DE STRASBOURG
2015 Phase 2 EUCTR2015-001716-36-FR France;
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
(RS)-baclofen, naltrexone hydrochloride and D-sorbitol
Pharnext SA
2021 Phase 3 NCT04762758 Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
ACE-083
Acceleron Pharma, Inc.
2019 Phase 2 NCT03943290 Canada;Spain;United States;
2017 Phase 2 NCT03124459 United States;
ACIDO ASCORBICO
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
ACIDO ASCORBICO DC.IT
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
Ascorbic acid
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2006 Phase 2 NCT00271635 Netherlands;
Chiba University
2019 Phase 1 JPRN-UMIN000036332 Japan;
New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare.
2005 Phase 1,2 JPRN-UMIN000001535 Japan;
SHIOHAMA TADASHI
2019 Phase 2 JPRN-jRCTs031190109 Japan;
Ascorbic acid (Vitamin C)
Wayne State University
2007 Phase 2/Phase 3 NCT00484510 United States;
Ascorbic acid vit C
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
BACLOFENE
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Baclofen
Pharnext
2010 - EUCTR2010-023097-40-FR France;
CEBION 500*20CPR MAST
ISTITUTO NEUROLOGICO CARLO BESTA
2004 - EUCTR2004-004501-24-IT Italy;
CEBION 500MG 20CPR MAST.ARAN
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
Coenzyme Q10
Memorial Medical Center
2007 Phase 1/Phase 2 NCT00541164 United States;
D-BIOTIN
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France;
D-SORBITOL
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
ElleOne
HÔPITAUX UNIVERSITAIRES DE STRASBOURG
2015 Phase 2 EUCTR2015-001716-36-FR France;
FLX-787-ODT (orally disintegrating tablet)
Flex Pharma, Inc.
2017 Phase 2 NCT03254199 United States;
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France;
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France;
Mexiletine
University of Rochester
2015 Phase 2 NCT02561702 United States;
NALTREXONE CLORIDRATO
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
NALTREXONE HYDROCHLORIDE
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Naltrexone
Pharnext
2010 - EUCTR2010-023097-40-FR France;
Naltrexone hydrochloride
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Non applicable
Pharnext
2010 - EUCTR2010-023097-40-FR France;
PXT3003
Pharnext
2010 - EUCTR2010-023097-40-FR France;
Pharnext SA
2022 Phase 3 EUCTR2020-004805-30-DK Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-NL Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-FR Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2021 Phase 3 EUCTR2020-004805-30-ES Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
2017 Phase 3 NCT03023540 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2020-004805-30-DE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
- Phase 3 EUCTR2020-004805-30-BE Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
PXT3003 Dose 1
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 Dose 2
Pharnext
2017 Phase 3 EUCTR2015-002379-81-FR Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-BE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 Dose 2 (equivalent to twice Dose 1)
Pharnext
2017 Phase 3 EUCTR2015-002379-81-DE Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2018 Phase 3 EUCTR2015-002379-81-NL Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2015-002379-81-GB Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 High Dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 Intermediate Dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 Low dose
Pharnext SA
2010 Phase 2 NCT01401257 France;
PXT3003 dose 1
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2015 Phase 3 NCT02579759 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
PXT3003 dose 2
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
Pharnext SA
2015 Phase 3 NCT02579759 Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
RS-BACLOFEN
PHARNEXT
2016 Phase 3 EUCTR2015-002378-19-DE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-FR Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2015-002378-19-ES Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002378-19-GB Belgium;France;Germany;Netherlands;United Kingdom;United States;
PHARNEXT SA
2016 Phase 3 EUCTR2015-002378-19-NL Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002378-19-BE Belgium;Germany;Netherlands;Spain;United Kingdom;United States;
SODIO ASCORBATO DC.IT
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2006-000032-27-IT Italy;
SORBITOLO
Pharnext SA
2021 Phase 3 EUCTR2020-004805-30-IT Belgium;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Spain;United States;
Sorbitol
Pharnext
2010 - EUCTR2010-023097-40-FR France;
ULIPRISTAL ACETATE
HÔPITAUX UNIVERSITAIRES DE STRASBOURG
2015 Phase 2 EUCTR2015-001716-36-FR France;